Exelixis (EXEL) Change in Inventory (2013 - 2026)
Exelixis (EXEL) posted quarterly Change in Inventory of $3.4 million for Q2 2026, up 4673.24% year-over-year from $71000.0 in Q2 2025, and up 124.55% quarter-over-quarter from -$13.8 million in Q1 2026.
Analysis
Exelixis (EXEL) Change in Inventory (2013 - 2026) Analysis & Trends
Exelixis' Change in Inventory history runs 14 years deep, the most recent figure standing at $3.4 million for Q2 2026.
- In Q2 2026, Change in Inventory rose 4673.24% year-over-year to $3.4 million; the TTM figure through Apr 2026 stood at -$8.9 million (down 142.9% YoY), while the FY2026 annual figure was -$12.2 million, down 124.19% from the prior year.
- Change in Inventory for Q2 2026 stood at $3.4 million, up from -$13.8 million in the prior quarter.
- The five-year high for Change in Inventory was $8.4 million in Q1 2023, with the low at -$13.8 million in Q1 2026.
- The 5-year median for Change in Inventory is $1.5 million (2022), against an average of $610058.8.
- Peak annual rise in Change in Inventory reached 4673.24% in 2026, while the deepest fall reached 399.86% in 2026.
- Exelixis' Change in Inventory stood at $1.8 million in 2022, then slumped by 182.62% to -$1.5 million in 2023, then soared by 125.16% to $384000.0 in 2024, then surged by 980.47% to $4.1 million in 2025, then dropped by 18.32% to $3.4 million in 2026.
- Business Quant data shows EXEL's Change in Inventory at $3.4 million in Q2 2026, -$13.8 million in Q1 2026, and $4.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 28.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 132.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 47.15 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -280,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 12.97 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 44,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 44,000.00 |
| Apr 3, 2026 | 3.39 Mn |
| Jan 2, 2026 | -13.81 Mn |
| Oct 3, 2025 | 4.15 Mn |
| Jul 4, 2025 | -2.64 Mn |
| Apr 4, 2025 | 71,000.00 |
| Jan 3, 2025 | -2.76 Mn |
| Sep 27, 2024 | 384,000.00 |
| Jun 28, 2024 | -1.36 Mn |
| Mar 29, 2024 | -1.72 Mn |
| Dec 29, 2023 | -1.53 Mn |
| Sep 29, 2023 | 1.69 Mn |
| Jun 30, 2023 | 4.45 Mn |
| Mar 31, 2023 | 8.37 Mn |
| Dec 30, 2022 | 1.85 Mn |
| Sep 30, 2022 | 1.51 Mn |
| Jul 1, 2022 | 4.80 Mn |
| Apr 1, 2022 | 3.52 Mn |
| Dec 31, 2021 | -13.75 Mn |
| Oct 1, 2021 | 18.94 Mn |